



# Translational Medicine Alliance

## 2010 FORUM

### AGENDA

---

#### Wednesday, October 13

6:00–7:00 PM

##### Reception and Networking

Location: Foyer, Grand Ballroom A and B

7:00–9:00 PM

##### Welcome Dinner

Location: Grand Ballroom A and B

8:00 PM

Remarks by David Ewing Duncan on *The Personalized Health Manifesto*: An old-fashioned call to arms and action plan for a new age of health care.

#### Thursday, October 14

7:00–7:45 AM

##### Breakfast

Location: Foyer, Grand Ballroom A and B

7:45–8:00 AM

##### Welcome and Opening Address

Location: Grand Ballroom A and B

Welcome

*Lesa Mitchell*

*Ewing Marion Kauffman Foundation*

*Margaret A. Anderson*

*FasterCures*

*Debra R. Lappin*

*Council for American Medical Innovation*

8:00–8:45 AM

##### Keynote Address

*Beat E. Widler, PhD*

*F. Hoffmann-La Roche Ltd.*



# Translational Medicine Alliance

## 2010 FORUM

Thursday, October 14 (cont)

8:45–9:30 AM

### **Data Access and Transparency Through Pre-Competitive Platforms**

Accelerating the pace of translating scientific discovery into viable medical solutions will rely in large part on accessible and transparent data from quality sources. There is increasing awareness from within the research and advocacy community for the need to develop pre-competitive platforms for these data. This panel will define the barriers to data transparency and access and identify the opportunities to accelerate science.

Moderator

*Debra R. Lappin*  
*Council for American Medical Innovation*

Panelists

*Aneesh Chopra*  
*Office of Science & Technology Policy*  
*The White House*

*Stephen H. Friend, MD, PhD*  
*Sage Bionetworks*

*Heather Joseph*  
*SPARC*

*John Wilbanks*  
*Creative Commons*

9:30–10:00 AM

### **Networking Break**

Location: Foyer, Grand Ballroom A and B

10:00–10:45 AM

### **Future Role of Academic Research in Translational Medicine**

Location: Grand Ballroom A and B

Ongoing scientific and technological advances, greater demand for tangible returns on federal investment in science, and new innovative models in translational medicine are among the forces transforming the medical research enterprise. What role will academic institutions play, to truly advance 21<sup>st</sup> century medicine? What leadership role should the NIH play, and which federal programs need to be advanced if we are to truly move translational medicine forward?

Moderator

*Sharon Begley*  
*Newsweek*

Panelists

*Regis B. Kelly, PhD*  
*QB3*

*Usama Malik, MBA*  
*Pfizer, Inc.*

*George Poste, DVM, PhD, RFS*  
*Arizona State University*



# Translational Medicine Alliance

## 2010 FORUM

### Thursday, October 14 (cont)

10:45–11:30 AM

#### **Reverse Engineering: Patient-Driven Translational Science**

From advocacy efforts to electronic health records; from biospecimen donation to participation in clinical trials, patients and their data drive medical research. And yet, oftentimes, while research programs acknowledge patients as the ultimate beneficiary, patients are not engaged to drive the process. This panel will explore a medical research system that starts, ends, and is driven by the needs of the patient. What will a patient-driven system look like and how will it be shaped?

Moderator

*Margaret A. Anderson  
FasterCures*

Panelists

*Frank Douglas, MD, PhD  
Austen BioInnovation Institute in Akron*

*Susan M. Love, MD, MBA  
Dr. Susan Love Research Foundation*

*Franklyn G. Prendergast, MD, PhD  
Mayo Clinic*

11:30 AM–12:45 PM

#### **Lunch**

#### **The Way Forward for Translational Medicine in the US**

Moderator

*Lesa Mitchell  
Ewing Marion Kauffman Foundation*

*Anna D. Barker, PhD  
Former Deputy Director, National Cancer Institute  
(Current—Private Consultant)*

*George Poste, DVM, PhD, RFS  
Arizona State University*

12:45–1:15 PM

#### **Networking Break**

Location: Foyer, Grand Ballroom A and B



# Translational Medicine Alliance

2010 FORUM

## Thursday, October 14 (cont)

1:15–2:00 PM

### How Rare Disease and Pediatric Medicine Research Are Changing the Landscape

Location: Grand Ballroom A and B

Medical innovations for pediatric and rare disease patients provide the enterprises' greatest challenges and opportunities. As we continue to develop more effective and efficient models, medical researchers in rare diseases and pediatrics are paving the way for patient-driven, outcomes-oriented, high-risk with high-reward potential approaches that have and will continue to yield results. Panelists will focus on how these models are being implemented, key barriers, and what needs to be done to leverage the current outcomes.

Moderator

*Elie Dolgin, PhD  
Nature Medicine*

Panelists

*Christopher P. Austin, MD  
National Institutes of Health*

*Atul Butte, MD, PhD  
Stanford University School of Medicine*

2:00–2:45 PM

### Regulatory Science – What's at Stake

This panel will delve deep into what's prompting the FDA's resounding call for greater regulatory science. What are the consequences of a regulatory agency that does not have the necessary scientific expertise and adequate resources? How will regulatory science—or the lack thereof—impact novel therapies in the pipeline? How can advances in this field modernize therapeutic research and development and spur greater investments in translational medicine?

Moderator

*Timothy R. Franson, MD  
B & D Consulting*

Panelists

*Vicki L. Seyfert-Margolis, PhD  
Science Innovation and Policy, FDA*

*Ellen V. Sigal, PhD  
Friends of Cancer Research*

*Jay J. Schnitzer, MD, PhD  
Boston Scientific Corporation*

*Scott J. Weir, PharmD, PhD  
Institute for Advancing Medical Innovation*



# Translational Medicine Alliance

2010 FORUM

Thursday, October 14 (cont)

2:45-3:30 PM

## Rethinking Everything

If we were starting over, what would we do differently?

Moderator

*Lesa Mitchell*

*Ewing Marion Kauffman Foundation*

Panelists

*Jonathan Jacoby*

*The R.A.R.E. Project*

*Scott Johnson*

*Myelin Repair Foundation*

*Lt Col Daniel J. Wattendorf, MD*

*DARPA*

3:30-3:45 PM

Closing Remarks